Increasing incidence of Clostridium difficile ribotype 001 associated with severe course of the infection and previous fluoroquinolone use in the Czech Republic, 2015

Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2251-2258. doi: 10.1007/s10096-017-3055-z. Epub 2017 Jul 5.

Abstract

The aim of the study was to provide an update on the epidemiology of C. difficile infection (CDI) in a representative number of hospitals within the Czech Republic in 2015. In 2015, twenty-eight Czech hospitals were invited to participate in a CDI study. Laboratories sent the first 20 consecutive C. difficile isolates for characterization by capillary-electrophoresis (CE) ribotyping and the presence of toxin genes and collected patient data on previous hospitalization, antibiotic treatment, the number of CDI episodes and the course of CDI. The mean incidence of CDI was 5.2 [95% CI 4.2-6.2] cases per 10,000 patient-bed days in 27 hospitals in 2015. Of 490 C. difficile isolates, the prevalent PCR ribotypes (RTs) were 001 (n = 164, 33.5%) and 176 (n = 125, 25.5%) followed by 014 (n = 37, 7.6%), 012 (n = 17, 3.5%), 020 (n = 16, 3.3%), 017 (n = 14, 2.9%) and 002 (n = 11, 2.2%). A severe course of CDI was reported in 104 cases (21.2%) with significant association with RT001 infection (p = 0.03). CDI recurrence was 10.8% (n = 53). The previous use of fluoroquinolones was associated with RTs 001 and 176 CDIs (p = 0.046 and p = 0.041). We observed a persistence of RTs 001 and 176 CDIs in the Czech Republic that was associated with the previous use of fluoroquinolones. This highlights the need for a reduction in fluoroquinolone use in Czech hospital settings.

Keywords: CDI surveillance; Capillary electrophoresis ribotyping; Clostridium difficile; Clostridium difficile infection; Fluoroquinolones; Toxin genes.

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Clostridioides difficile / classification*
  • Clostridioides difficile / genetics
  • Clostridioides difficile / isolation & purification
  • Cross Infection / epidemiology
  • Cross Infection / microbiology
  • Czech Republic / epidemiology
  • Drug Resistance, Bacterial / physiology*
  • Enterocolitis, Pseudomembranous / drug therapy*
  • Enterocolitis, Pseudomembranous / epidemiology*
  • Enterocolitis, Pseudomembranous / microbiology
  • Fluoroquinolones / therapeutic use*
  • Hospitals
  • Humans
  • Ribotyping

Substances

  • Anti-Bacterial Agents
  • Fluoroquinolones